Fetuin-A is a liver protein known to induce insulin resistance.
Novelty and Impact:
Fetuin-A is a liver protein known to induce insulin resistance.
Hyperinsulinemia is a possible risk factor for colorectal cancer, but whether fetuin-A plays a role in the etiology of colorectal cancer is currently unclear. In this prospective study, we found a modest linear association between fetuin-A and higher risk of colorectal cancer, but genetically raised fetuin-A was unrelated to colorectal cancer risk, arguing against a direct role of fetuin-A in colorectal carcinogenesis. 
Introduction
Fetuin-A, also referred to as α2-Heremans-Schmid glycoprotein (AHSG), is a protein that is almost exclusively expressed and secreted by the liver, particularly in nonalcoholic fatty liver disease (NAFLD) 1 . Fetuin-A plays a role in the insulin signaling pathway, acting as an inhibitor of insulin receptor tyrosine kinase 2 . Mice deficient for the AHSG gene displayed improved insulin sensitivity, lower body weight and were resistant to weight gain upon a high-fat diet 3, 4 .
Further experimental studies in rodents have shown that fetuin-A induces insulin resistance 5 .
These findings are supported by a number of human studies that observed positive associations between circulating fetuin-A and measures of insulin resistance 1, 6, 7 . In addition, a bidirectional
Mendelian Randomization study suggested a causal relationship between fetuin-A and body mass index 8 . Recently, positive associations between fetuin-A concentrations and risk of type 2 diabetes 9-11 and cardiovascular disease 12, 13 have been observed in large prospective studies.
Insulin resistance and associated metabolic states such as hyperinsulinemia, hyperglycemia, lowgrade inflammation and hypoadiponectinemia have been associated with increased risk of colorectal cancer in several prospective studies 14 including the European Prospective Investigation into Cancer and Nutrition (EPIC) [15] [16] [17] [18] . However, it is currently unknown whether fetuin-A plays a role in the development of colorectal cancer. Therefore, we aimed to investigate the association between circulating fetuin-A and risk of colorectal cancer in a prospective nested case-control study in EPIC. Because observational studies relating circulating biomarker concentrations to risk of disease may be affected by residual confounding and reverse causation, even in a prospective study design, we additionally aimed to examine potential causality by using single nucleotide polymorphisms (SNPs) in the AHSG gene as relatively unbiased proxies for fetuin-A concentration using a Mendelian Randomization approach 19 .
Material and Methods

Study population
The EPIC study is an ongoing cohort study with over 520,000 participants from 23 centers in 10
Western European countries who were between 25 and 70 years old at study recruitment in the period between 1992 and 2000. Details on the methods of the EPIC study design were reported previously 20 . Briefly, standardized lifestyle and personal history questionnaires, anthropometric data and blood samples were collected from most participants at recruitment, prior to disease onset or diagnosis. Diet over the previous 12 months was assessed at recruitment by validated country-specific questionnaires. The EPIC study was approved by the ethics review board of the International Agency for Research on Cancer (IARC, Lyon, France) and the local review boards of the participating institutions.
Identification of colorectal cancer cases
Incident cancer cases were identified through record linkage with regional cancer registries in most participating countries (Denmark, Norway, the Netherlands, Spain, Sweden, UK and most of the Italian study centers). In France, Germany, Greece and Naples (Italy), follow-up was performed actively by the participants or their next of kin through mailed questionnaires. Selfreported cancer cases were then verified by study physicians using health insurance data, information from cancer and clinical registries, and medical records provided by treating physicians. The closure dates, which were defined as the latest date of complete follow-up for were overlapping or unspecified (C18.8-C18.9), and tumors of the rectum (C19-C20).
Nested case-control study
A total of 1,367 first incident colorectal cancer cases with available questionnaire data and blood samples were included in the study. For each case one control was selected using an incidence density sampling approach from all cohort members who were alive and free of cancer at the time of diagnosis of the index case. Matching factors included sex, age at blood collection (2-months to 4-year intervals), study center, time of blood collection (±4 hours) and fasting status (<3, 3-6, or >6 hours). Women were additionally matched on menopausal status (premenopausal, perimenopausal, postmenopausal, or surgically menopausal). Premenopausal women were matched on phase of the menstrual cycle at blood collection (early follicular, late follicular, ovulatory, early luteal, mid-luteal, or late luteal), and postmenopausal women were matched on current use of hormone replacement therapy (yes/no). Of note, not all matching factors (e.g. menstrual cycle) were relevant for the present study, since the case-control set was designed to be used for several biomarker studies.
DNA was available for 1,110 participants (627 colorectal cancer cases, 483 control participants, 456 case-control pairs), largely due to unavailability of DNA samples from the Danish EPIC centers (due to local technical and organizational circumstances that delayed sample retrieval ) and a proportion of empty DNA tubes throughout all study centers. Comparison of baseline characteristics of control participants with DNA (n=483) with control participants excluded from the genetic analyses in this study due to unavailable DNA (n=970) revealed that both groups were similar with regards to gender, age, education, and body fatness.
Laboratory measurements
At baseline, blood samples were collected from participants using a standardized protocol and inter-assay coefficient of variation was 8.1%.
Five tagging single nucleotide polymorphisms (SNPs) in the AHSG gene (rs2248690, rs2070633, rs2070635, rs4917 and rs6787344) were selected via HapMap applying stringent criteria (minor allele frequency >5% and pairwise r 2 ≥0.80), and genotyped using TaqMan methodology.
Genotype call rates were >99.2% for all assays.
Circulating concentrations of C-peptide, HbA1c, insulin-like growth factor 1 (IGF-1), total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), adiponectin, leptin, and soluble leptin receptor (sOB-R), were also available and methods for their measurement are described elsewhere 15, 17, 18, 21, 22 .
Statistical analysis
Baseline characteristics between cases and controls were compared using paired t-test, Wilcoxon signed rank test, or Mc Nemar's test. Spearman partial correlation coefficients, adjusted for age and sex, were calculated in control participants to examine the relationship between fetuin-A and age (sex-adjusted only), body mass index, waist circumference, physical activity, alcohol intake and metabolic biomarkers.
The association between circulating fetuin-A and risk of colorectal (overall, and separately by sex), colon or rectal cancer was evaluated using conditional logistic regression analysis calculating odds ratios (ORs) and 95% confidence intervals (95% CI). Because of the incidence density sampling, ORs approximate incidence rate ratios which can be interpreted as relative risks. Data were analyzed by quintiles of fetuin-A concentrations with cut-offs based on the distribution among control participants. Test for trend across quintiles was performed by entering the quintile medians as continuous variable to the conditional logistic regression model and evaluating its significance by using the Wald-test. We also examined fetuin-A as a continuous variable by increments of 40 µg/mL (approximately one standard deviation in fetuin-A concentration). We tested for potential non-linear associations between fetuin-A and risk of colorectal cancer using fractional polynomials 23 . ORs were evaluated in a crude model conditioned on matching factors only as well as in a multivariable model with adjustment for potentially confounding factors including education, Cambridge physical activity index 24 , smoking status, alcohol intake, total energy intake, fiber intake, fruit and vegetable intake, red meat intake, processed meat intake and fish and shellfish intake (model 1). Because risk estimates from crude models did not differ appreciably from multivariable models, only multivariable estimates were presented. In a separate model, we added body mass index (BMI) and residuals of BMI-adjusted waist circumference (to avoid multicollinearity) as covariables (model 2) to examine whether adjustment for body fatness changed risk estimates. There were 128 participants with missing values on waist circumference in whom the waist circumference residuals were substituted with sex-specific median values. In addition, in four participants who had no information on dietary intake, sex-specific median dietary intake values were imputed for analysis. Potential heterogeneity in the associations between fetuin-A and colon versus rectal cancer was determined using competing risk analysis 25 . Heterogeneity by sex was evaluated using the Q-statistic from the inverse variance method 26 .
Additional analyses were performed with exclusion of cases (and their matched controls) diagnosed within 2 years after recruitment (n=217 cases, 16% of all cases) to evaluate whether our findings may be influenced by reverse causation due to preclinical disease.
Furthermore, we additionally adjusted for metabolic biomarkers which were significantly correlated with fetuin-A and have been shown to be independent risk factors for colorectal cancer in previous studies in EPIC 17, 18, 22 , including C-peptide, HbA1c, and sOB-R. In order to examine C-peptide and HbA1c simultaneously, we added a factor score resulting from factor analysis on both variables to the model 27 . A dataset containing observations with available data on all these biomarkers was created, which included 465 case-control pairs (the lower number is because HbA1c and C-peptide were assayed only for part of the dataset).
We also conducted analyses stratified by median age (</≥ 59 years), categories of BMI (<25, 25-30, ≥30 kg/m 2 ), waist circumference (<88 cm in women or <102 cm in men versus ≥88 cm in women or ≥102 cm in men), HbA1c (<5.7%, ≥5.7%), C-peptide (<4.5 ng/mL in men or <3.4 ng/mL in women versus ≥4.5 ng/mL in men or ≥3.4 ng/mL in women) and tertiles of sex-specific alcohol intake. Because numbers of case-control pairs were small in certain strata, stratified analyses were conducted using unconditional logistic regression models, adjusting for matching variables and all potential covariables included in model 2 (excluding the stratifying variable).
Potential effect modification (statistical interaction on the multiplicative scale) was evaluated by including a product term of stratifying factors (median values of categories) and fetuin-A (continuously) in the model and evaluating its statistical significance using Wald's test. 
Results
Incident colorectal cancer cases had at baseline a higher BMI and a higher waist circumference and were more often physically inactive than matched control participants (Table 1 ). Dietary intake of fiber was lower in colorectal cancer cases than in control participants. Median prediagnostic blood concentrations of fetuin-A were 227.7 µg/mL in colorectal cancer cases and 225.1 µ/mL in matched control participants. Compared with their matched controls, colorectal cancer cases had higher pre-diagnostic blood concentrations of C-reactive protein, and lower concentrations of HDL cholesterol, adiponectin and sOB-R.
In control participants, plasma fetuin-A was significantly, albeit weakly, positively correlated with BMI (r=0.14, p-value <0.0001) and waist circumference (r=0.16, p-value <0.0001), and inversely correlated with age (r=-0.07, p-value 0.01) and alcohol consumption (-0.09, p-value 0.001). Of the metabolic biomarkers, C-peptide (r=0.08, p-value 0.05), HbA1c (r=0.12, p-value 0.01) and triglycerides (r=0.09, p-value 0.02) were weakly positively correlated with fetuin-A, and sOB-R (r=-0.09, p-value 0.02) was inversely correlated with fetuin-A (supplemental table 1).
C-reactive protein, IGF-1, total cholesterol, adiponectin, and leptin were not significantly correlated with fetuin-A (all p-values >0.09).
Each 40 µg/mL fetuin-A increment (approximately one standard deviation) was significantly associated with a 13% higher risk of colorectal cancer (OR 1.13, 95% CI 1.02, 1.24) before, and a 11% higher risk of colorectal cancer (OR 1.11, 95% CI 1.01, 1.22) after adjustment for body fatness (Table 2 ). No such association was seen when comparing the highest with the lowest quintile. Using fractional polynomials with between one and two degrees, we found no evidence that a non-linear function was statistically superior to the linear model (all p-values for nonlinearity >0.10). In analyses by sex, plasma fetuin-A concentrations were significantly positively associated with colorectal cancer risk in men both in continuous and categorical analyses (Table   3 ). In contrast, no association was observed in women. However, we did not observe statistically 
Discussion
In this prospective study, we found a modest positive association between plasma fetuin-A concentrations and risk of colorectal cancer, adjusting for a variety of potentially confounding factors. However, significant associations were only observed when fetuin-A was modeled as a continuous variable, and not when comparing quintiles of fetuin-A concentrations. Furthermore, associations were restricted to male participants, while no statistically significant associations were observed in women. The observed associations between fetuin-A and risk of colorectal cancer were only slightly attenuated after adjustment for body fatness and were not substantially influenced by additional adjustment (in a subset) for C-peptide or HbA1c. In contrast to these observations, genetically raised fetuin-A concentrations were not associated with a higher risk of colorectal cancer in the Mendelian Randomization analysis, arguing against the hypothesis that plasma fetuin-A concentrations play a causal role in colorectal carcinogenesis.
To our knowledge this is the first prospective study to examine circulating fetuin-A However, the attenuation was small and may also be due to chance. It is currently unclear how preclinical colorectal cancer may result in an upregulation of fetuin-A expression, but in a recent proteomics study, a fetuin-A precursor was found to be up-regulated in post-diagnostic plasma of colorectal cancer patients as compared to healthy volunteers and authors suggested this precursor as potential diagnosis marker for colorectal cancer 38 . In contrast, in a small cross-sectional study comparing fetuin-A concentrations between 32 colorectal cancer patients and 30 control participants no differences were observed 39 .
Within the limits of our study we tried to control for potential confounding as completely as possible in our analysis. However, an uncontrolled or insufficiently controlled environmental or lifestyle factor associated with both fetuin-A and colorectal cancer may have influenced our findings on plasma fetuin-A concentrations and risk of colorectal cancer. Therefore, besides reverse causation, the observed significant association of measured circulating fetuin-A and colorectal cancer may also be explained by residual confounding. This is in contrast to the null association found in our Mendelian Randomization analysis, which circumvents reverse causation and uncontrolled confounding 18, 28, 30 , thus suggesting that fetuin-A has no causal role for colorectal cancer.
The limited sample size for the Mendelian Randomization analysis is a limitation of our study.
Instrumental variable estimates can be biased when both the variance explained by the instruments and the sample size are small 29 . However, the selected polymorphisms in the AHSG gene were strong predictors of fetuin-A concentrations, explaining a good proportion of interindividual variation. Nevertheless, as reflected by the wide confidence interval of the instrumental variable estimate, our study had limited statistical power to detect small effects, and we cannot exclude that a modest association between genetically raised fetuin-A and colorectal cancer risk would have been detected in a Mendelian Randomization study with substantially larger sample size. Of note, in a previous Mendelian Randomization study in EPIC with a similar sample size, a significant association between genetically raised CRP and risk of colorectal cancer was observed, even though the instrument strength of the CRP-score was weaker than of the here applied AHSG-score 40 . It should also be noted that the AHSG-score was not completely independent of potentially confounding factors. Both BMI and soluble leptin-receptor differed significantly by tertiles of the AHSG-score. This finding, however, is consistent with studies showing that certain AHSG genotypes are more common in obese than in lean people 33 ; With respect to the analysis of the association between measured circulating fetuin-A and risk of colorectal cancer, random measurement error may have attenuated observed associations. It also is a limitation of our study that fetuin-A was measured only once at baseline and thus may not influenced fetuin-A values.
Strengths of our study include the prospective design, the ability to adjust for a variety of potentially confounding factors including metabolic biomarkers as well as the ability to investigate potential causality in a Mendelian Randomization approach using multiple AHSG genetic variants which were strongly associated with fetuin-A concentrations.
In conclusion, the findings of our study suggest that high fetuin-A concentrations are associated with a modest higher risk of colorectal cancer, but that fetuin-A may not be causally related to colorectal cancer development. Both, the basic association between circulating fetuin-A and risk of colorectal cancer as well as the lack of association between genetically raised fetuin-A and colorectal cancer risk warrant confirmation by further studies. 
